SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Webhead who wrote (1609)10/29/1998 8:32:00 PM
From: A.J. Mullen  Read Replies (1) of 1762
 
Webhead, I see you know something of which you speak. Please bear with me. I have only half-knowledge of facts and guesses, and the biggest problem is that I am not sure which is which.

I can see now the logic of mopping up circulating lymphocytes before labelling. I am still troubled by Maurices' idea that Rituxan will harden the CD20. You say most cell-surface proteins turn over rapidly once labelled, but isn't that the idea of Rituxan. If Rituxan hasn't worked, is that not because some cd20-Rituxan conjugates are stable?
The press-release mentioned YT-rituxan treatment being administered over eight days.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News